In this article, we will be taking a look at the 5 biggest health care companies in Australia, 2024. If you wish to learn about more, head straight to the 20 Biggest Health Care Companies in Australia, 2024.
5. EBOS Group Limited
Market Cap: $4.098 billion
EBOS Group Limited, a major player in the healthcare industry, specializes in marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products across Australia, New Zealand, and Southeast Asia. Established in 1922, the company boasts over 5,000 employees and operates through Healthcare and Animal Care segments. The Q4 2023 financial report highlights a revenue growth of 5.9%.
4. Pro Medicus Limited
Market Cap: $6.54 billion
Pro Medicus Limited, one of the biggest health care companies in Australia in 2024, offers advanced medical imaging software and services to hospitals, imaging centers, and healthcare groups globally. With products like Visage RIS and Visage 7, the company provides clinicians with cutting-edge visualization capabilities for medical images. Their PACS and digital imaging software streamline image management and communication within healthcare facilities. In Q4 2023, revenue from ordinary activities increased by 30.3% to $74.1 million.
3. ResMed Inc
Market Cap: $28.24 billion
ResMed Inc., a leading healthcare company, specializes in digital health technology and respiratory care solutions. Founded in 1989, ResMed is globally recognized for its innovative CPAP technology for sleep apnea. With a comprehensive range of devices and software, ResMed empowers individuals to manage their health conditions from home. In Q4 2023, ResMed reported a 23% year-over-year revenue growth, an 8% increase in operating profit, and a 9% rise in quarterly dividend to $0.48 per share.
2. Cochlear Limited
Market Cap: $15.9 billion
Cochlear Limited, a healthcare leader in implantable hearing solutions since 1981, invests heavily in R&D, exceeding $180 million annually. Their innovative products, including the Cochlear Osia 2 System and Cochlear Nucleus sound processors, have transformed the lives of over 600,000 individuals with hearing loss. Cochlear advocates for policies enhancing accessibility to hearing implants. In Q1 2024, the company reported a significant revenue increase of 24%, reaching AU$1.1 billion, with net income at AUD 191.4 million, and basic earnings per share of AUD 2.919.
1. CSL Limited
Market Cap: $101.8 billion
CSL Limited, one of the biggest health care companies in Australia in 2024 and a leading biotechnology company in Australia, operates through three main segments: CSL Behring, CSL Seqirus, and CSL Vifor. CSL Behring focuses on plasma products and gene therapies, CSL Seqirus specializes in influenza vaccines, and CSL Vifor deals with iron deficiency products. CSL Behring develops therapies for various medical conditions, while CSL Seqirus plays a vital role in global influenza prevention. CSL Vifor contributes to improving the lives of patients with iron deficiency. In Q4 2023, CSL reported a net profit after tax of $2.61 billion, a 20% increase at constant currency, and a 31% revenue increase due to strong performance, especially in immunoglobulin sales. The acquisition of Vifor Pharma was successfully completed, and HEMGENIX, the first gene therapy for hemophilia B, was FDA-approved.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also take a peek at the 15 Hungriest States in the US and the 20 US Cities with the Most Million-Dollar Homes.
